Reflex testing of resected stage i through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center
DNA Mutational Analysis
Receptor, Epidermal Growth Factor
The results of the first 3 years of reflex testing at MSKCC reported here demonstrate the feasibility, clinical utility, and potential of this approach. This information allowed for enrollment of patients into clinical trials to explore mutation-specific, directed therapy and led to retrospective studies related to patient outcome. In addition, it may inform selection of chemotherapy for recurrent disease and may help to distinguish multiple primary tumors from metastatic disease.